Loading…

Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B

Background and Aims Improvement in Model for End‐Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)‐related cirrhosis. We aimed to identify factors associated with transplant‐free survival...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-09, Vol.35 (9), p.1610-1618
Main Authors: Yip, Terry Cheuk‐Fung, Lee, Hye Won, Wong, Vincent Wai‐Sun, Wong, Grace Lai‐Hung, Tse, Yee‐Kit, Lui, Grace Chung‐Yan, Ahn, Sang Hoon, Chan, Henry Lik‐Yuen
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims Improvement in Model for End‐Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)‐related cirrhosis. We aimed to identify factors associated with transplant‐free survival and on‐treatment MELD score improvement. Methods We identified patients with CHB‐related cirrhosis and MELD score ≥ 15 at the start of entecavir and/or tenofovir disoproxil fumarate treatment between 2005 and 2017. The primary endpoint was transplant‐free survival at month 6. The secondary endpoints at month 6 were transplant‐free survival with > 5‐point improvement in MELD score and transplant‐free survival with MELD score  5‐point improvement in MELD score; 183 (30.2%) had 1‐point to 5‐point improvement in MELD score; 146 (24.1%) had no improvement or a worsened MELD score. Also, 321 (53.1%) patients with transplant‐free survival had a MELD score 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15007